The field of molecular imaging is undergoing a period of expansion. The number of
radiopharmaceutical ligands, therapeutic isotope combinations, and targets continues to …

Radiotracers, or radiopharmaceuticals, are bioactive molecules tagged with a radionuclide
used for diagnostic imaging or radiotherapy and, when a positron-emitting radionuclide is …

With new radiopharmaceuticals constantly in development, the field of nuclear medicine is
ever evolving. This continuing education article reviews some of the newer, less frequently …

While the development of positron emission tomography (PET) radiopharmaceuticals
closely follows that of traditional drug development, there are several key considerations in …

The development of PET radiopharmaceuticals for the non-invasive imaging of cancerous
lesions, brain receptors, transporters and enzymes started more than 25 years ago. But till …

In PET imaging, the major driving force is novel and innovative radiopharmaceuticals.
Access to such radiopharmaceuticals is given by the field of PET chemistry. PET chemistry …

Although 18 F-fluorodeoxyglucose (18 F-FDG) is still the most widely used positron emission
tomography (PET) radiotracer, there are a few well-known limitations to its use. The last …

The vast majority of PET radiopharmaceuticals today are cyclotron produced. Carbon-11 (11
C), Nitrogen-13 (13 N), Oxygen-15 (15 O) products are created for in-house use only due to …

In this review we provide a conceptual overview of radiopharmaceuticals containing positron-
emitting isotopes, not a catalog of radiopharmaceuticals or details of syntheses. We hope to …

This review article discusses PET agents, other than 18 F-FDG, with the potential to monitor
the response to therapy before, during, or after therapeutic intervention. This review deals …